AstraZeneca PLC (LON:AZN) has been retained to Hold in a statement by Shore Capital earlier today.
- Updated: October 2, 2016
Just yesterday AstraZeneca PLC (LON:AZN) traded -0.44% lower at 5,124.50GBX. AstraZeneca PLC’s 50-day moving average is 5,015.00GBX and its 200-day moving average is 4,398.79GBX. The last closing price is up 13.45% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 2,836,601 shares of AZN traded hands, up from an average trading volume of 2,654,930
Shore Capital has retained AstraZeneca PLC (LON:AZN) to Hold in a report released on 9/28/2016.
Recent Performance Chart
AstraZeneca PLC has 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX with a PE ratio of 28.52 and has a market capitalization of 0 GBX.
In addition to Shore Capital reporting its stock price target, a total of 29 brokers have issued a research note on the company. The average stock price target is 61.96GBX with 4 brokers rating the stock a strong buy, 14 brokers rating the stock a buy, 13 brokers rating the stock a hold, 2 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell.
Brief Synopsis On AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.